Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text
DOI
PMC
 |
Open Access Hybrid |
|
as soon as is submitted to ZB.
Liquid biopsies and those three little words: Finding the perfect match for the MTB.
Med. Genet. 35, 269-273 (2023)
Monitoring ctDNA by liquid biopsies seems to represent the perfect match for precision oncology and its cornerstone clinical framework: the molecular tumour board (MTB). Detecting and scrutinising the success of targeted therapies or tracking and, for that matter, addressing the therapy with the evolutive nature of a tumour are some of the main advancements one considers to be important for the MTB. One challenge is correlating the estimated allele frequency of each identified genetic alteration determined by analysing the ctDNA sequencing results and matching these with the range of suitable drugs, which may limit the simultaneous treatment of all tumour variations. This limitation arises because a new biopsy would typically be required to evaluate the response to treatment. As a result, evaluating the success of MTB recommendations relies on traditional staging methods, highlighting an existing diagnostic gap. Thus, optimising liquid biopsy technology could enhance the efficacy of MTB treatment recommendations and ensuing tailored therapies. Herein, we discuss the prospect of ctDNA analyses in the molecular tumour board.
Impact Factor
Scopus SNIP
Scopus
Cited By
Cited By
Altmetric
1.100
0.154
1
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Review
Keywords
Liquid Biopsy ; Molecular Tumor Board ; Mtb ; Next-generation Sequencing ; Ngs ; Precision Oncology ; Targeted Therapy; Circulating Tumor Dna; Mutations
Language
english
Publication Year
2023
HGF-reported in Year
2023
ISSN (print) / ISBN
0936-5931
e-ISSN
1863-5490
Journal
Medizinische Genetik
Quellenangaben
Volume: 35,
Issue: 4,
Pages: 269-273
Publisher
Springer
Publishing Place
Genthiner Strasse 13, D-10785 Berlin, Germany
Reviewing status
Peer reviewed
Institute(s)
Institute of Metabolism and Cell Death (MCD)
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Genetics and Epidemiology
PSP Element(s)
G-506900-001
WOS ID
001114621800023
Scopus ID
85179835754
PubMed ID
38835735
Erfassungsdatum
2024-01-10